单个吸入器与多个吸入器的COPD三重疗法的成本效益:德国医疗保健观点
Kai-Michael Beeh1, Jing Claussen2, Dhvani Shah3
1Insaf Respiratory Research Institute, Taunusstein, Germany.
概括
单个吸入器三重疗法 (SITT) 含有酸, umeclidinium 和 vilanterol (FF/UMEC/VI) 是在德国治疗 COPD 的临床效益和成本效益. 与多个吸入器三重疗法 (MITT) 相比,这种方法提供了更好的结果和成本节省.
科学领域:
- 肺部医学 肺部医学
- 卫生经济学 卫生经济学
背景情况:
- 慢性阻塞性肺病 (COPD) 管理需要有效和经济高效的治疗策略.
- 从INTREPID试验中获得的现实世界的证据表明,单吸入器三重治疗 (SITT) 的临床益处是使用酸, umeclidinium 和 vilanterol (FF/UMEC/VI) 的临床益处.
研究的目的:
- 评估FF/UMEC/VI SITT的成本效益与非ELLIPTA多次吸入器三重疗法 (MITT) 相比,用于德国有症状的COPD患者.
- 从德国医疗保健的角度评估FF/UMEC/VI的经济影响和临床益处.
主要方法:
- 在GALAXY COPD模型中填充了INTREPID试验的数据,包括治疗效果和中止率.
- 纳入了德国医疗保健资源和药物成本,并对终身时间进行了分析.
- 使用寿命年 (LY),质量调整后的 LY (QALY) 和增量成本效益比率来确定成本效益,并进行敏感性分析.
主要成果:
- 预计FF/UMEC/VI SITT与非ELLIPTA MITT相比,每名患者可提供额外的0.174 LY和0.261 QALY.
- 预计FF/UMEC/VI每名患者可节省2850欧元的费用,并减少恶化 (-0.063).
- 敏感性和概率分析证实了FF/UMEC/VI作为主导和具有成本效益的治疗选择的稳定性.
结论:
- 在德国,FF/UMEC/VI SITT为COPD治疗提供了显著的临床益处和成本节省.
- 这种疗法可以减少COPD的整体负担,应该被医生认为是首选的治疗选择.
相关概念视频
01:23Inhaled Medications
414
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
414
01:26COPD: Management Using Bronchodilators and Corticosteroids
329
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
329
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.7K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.7K
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
3.0K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.0K
01:30Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
2.6K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
2.6K